103 related articles for article (PubMed ID: 4004281)
21. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
22. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of recombinant methionyl human consensus interferon (r-metHuIFN-Con1).
Neidhart JA; Schmidt S; Rosenblum M; Raber MN; Quesada JR; Alton NK; Downing M
J Biol Response Mod; 1988 Jun; 7(3):240-8. PubMed ID: 3392552
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
Taguchi T
Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
[TBL] [Abstract][Full Text] [Related]
25. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
26. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
27. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of human leukocyte interferon in patients with advanced cancer.
Horning SJ; Levine JF; Meyer M; Merigan TC; Rosenberg SA
J Biol Response Mod; 1983; 2(1):47-56. PubMed ID: 6196450
[TBL] [Abstract][Full Text] [Related]
29. [Recombinant interferon alpha-2 (Sch 30500) in patients with head and neck cancer].
Miyake H; Horiuchi M; Togawa K; Kawamoto K; Kaneko T; Inuyama Y; Honda Y; Baba S; Matsunaga T; Ishikawa T
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1651-5. PubMed ID: 3896156
[TBL] [Abstract][Full Text] [Related]
30. Treatment of multiple myeloma with recombinant human leukocyte A interferon.
Ohno R; Kimura K; Amaki I; Imamura Y; Masaoka T; Miyazaki T; Yoshida Y; Miura Y; Maekawa T; Oguro M
Cancer Treat Rep; 1985 Dec; 69(12):1433-5. PubMed ID: 4075317
[TBL] [Abstract][Full Text] [Related]
31. Alpha(human leukocyte)-interferon as treatment for non-small cell carcinoma of the lung: a phase II trial.
Sarna G; Figlin R; Callaghan M
J Biol Response Mod; 1983; 2(4):343-7. PubMed ID: 6315898
[TBL] [Abstract][Full Text] [Related]
32. [The treatment of renal cell carcinoma with recombinant human leukocyte interferon].
Kawamura J; Yamauchi T; Hashimura T; Yoshida O; Kohnami T; Tomoyoshi T; Ogura K; Fukuyama T; Nakagawa K
Hinyokika Kiyo; 1985 Mar; 31(3):377-86. PubMed ID: 4025077
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma.
Goldberg RM; Ayoob M; Silgals R; Ahlgren JD; Neefe JR
Cancer Treat Rep; 1985; 69(7-8):813-6. PubMed ID: 4016791
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.
Figlin RA; Callaghan M; Sarna G
Cancer Treat Rep; 1983 May; 67(5):493-4. PubMed ID: 6850664
[TBL] [Abstract][Full Text] [Related]
35. [Effects of interferon on various malignancies].
Taguchi T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):194-204. PubMed ID: 6696457
[TBL] [Abstract][Full Text] [Related]
36. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs).
Sarna G; Figlin R; Bryson Y; Garratty E; Myers L; Le Fevre C; Mauritzon N; Cline M
Am J Clin Oncol; 1985 Oct; 8(5):406-12. PubMed ID: 4061375
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
38. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
Krown SE; Burk MW; Kirkwood JM; Kerr D; Morton DL; Oettgen HF
Cancer Treat Rep; 1984 May; 68(5):723-6. PubMed ID: 6722830
[TBL] [Abstract][Full Text] [Related]
39. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients.
Quesada JR; Gutterman JU
J Natl Cancer Inst; 1983 Jun; 70(6):1041-6. PubMed ID: 6190033
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Sarna GP; Figlin RA
Cancer Treat Rep; 1985 May; 69(5):547-9. PubMed ID: 4005877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
